Mourabit Halima, Author at MediaMedic

New Concepts in Regional Treatment of Breast Cancer and Future Outlook by Dr. Yongsheng Wang | 2024 CACA Integrated Breast Cancer Conference

By Mourabit Halima 2024.08.07

At the 2024 China Anti-Cancer Association (CACA) Integrated Breast Cancer Conference, Dr. Yongsheng Wang from Shandong Cancer Hospital elaborated on new concepts in regional treatment for breast cancer. He emphasized that local regional treatment for breast cancer patients should comprehensively consider the risk of recurrence and metastasis, the efficacy and adverse effects of systemic treatment, and the efficacy and adverse effects of local regional management. Professor Wang also proposed a new definition for axillary lymph node negativity and discussed individualized adjuvant radiotherapy strategies for patients with positive sentinel lymph node biopsy and new strategies for managing the internal mammary region. Following the conference, Oncology Frontier invited Professor Wang for an in-depth discussion on regional lymph node treatment.

Comprehensive Review of Chemotherapy-Induced Anemia Management in China （1）

By Mourabit Halima 2024.08.07

Cancer-related anemia (CRA) encompasses anemia that occurs in cancer patients during disease progression or treatment, including non-chemotherapy-related CRA and chemotherapy-induced anemia (CIA). With the increase in chemotherapy treatments, the incidence of anemia is significant, with over 90% of patients not receiving any corrective treatment. To gain a comprehensive understanding of the current practices and perceptions of Chinese clinicians in managing CIA and to improve the management level of CIA in China, Oncology Frontier initiated a "Survey on Chemotherapy-Induced Anemia in Cancer Patients," collecting 308 questionnaires from 28 provinces and cities across the country. The survey revealed that although the current management concepts of CIA in China still differ from existing guidelines, Chinese clinicians' awareness of CIA management is continually strengthening, contributing to the standardization of management for anemia related to new anti-cancer therapies.

CD7 CAR-T Combined with Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Improves Survival in r/r T-ALL/LBL Patients

By Mourabit Halima 2024.08.07

Relapsed/refractory acute T-cell lymphoblastic leukemia/T-cell lymphoblastic lymphoma (r/r T-ALL/LBL) presents significant treatment challenges with poor prognosis. Data show that the 5-year survival rate is less than 25%, and even with salvage allo-HSCT, the 3-5 year survival rate is only 14-30%. Improving survival for these patients has become a hot research topic. Recently, Professor Xingyu Cao's team at Beijing Lu Daopei Hospital conducted a study using CD7 CAR-T combined with allo-HSCT to treat r/r T-ALL/LBL, achieving notable efficacy and reliable safety. This study was published in the British Journal of Haematology (BJH). Oncology Frontier - Hematology Frontier interviewed Professor Cao to discuss the treatment of r/r T-ALL/LBL. Here are the details.

The Next “Berlin Patient”? The 7th Global HIV Cure Case Emerges!

By Mourabit Halima 2024.08.06

The "Berlin Patient" is renowned as the first person in the world to be cured of HIV, marking a significant milestone in medical history. Over a decade later, the pioneering team at Germany’s Charité – Universitätsmedizin Berlin has announced the successful treatment of the "Next Berlin Patient," representing the 7th global case of HIV cure. Publicly available data indicates that this patient has remained virus-free for over five years without antiretroviral therapy (ART). What sets this case apart is that the treatment method differed from those used in previous cures. Detailed treatment information will be presented at the 25th International AIDS Conference (AIDS 2024) in Munich on July 24.

SYK Inhibitors at EHA | Dr. Zeping Zhou: Mechanistic Insights into HMPL-523, a Promising SYK Inhibitor for ITP Treatment

By Mourabit Halima 2024.08.06

The annual meeting of the European Hematology Association (EHA) is a premier international conference that gathers experts and scholars from around the globe to share and discuss innovative ideas and advancements in scientific and clinical research in the field of hematology. This year, the research on spleen tyrosine kinase (SYK) inhibitors has garnered significant attention. HMPL-523 (Solepinib), the first domestically produced SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. "Oncology Frontier - Hematology Frontier" invited Dr. Zeping Zhou from The Second Affiliated Hospital of Kunming Medical University to interpret the ESLIM-01 study (NCT05029635) on Solepinib for primary immune thrombocytopenia (ITP), aiming to provide clinical practice references.

EHA International Perspectives丨Dr. Swaminathan Iyer: ELA026 Efficacy in Treatment-Naive mHLH Patients

By Mourabit Halima 2024.08.06

Malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) is a highly aggressive and fatal disease, with innovative treatment strategies being a major focus and challenge in hematology research. Recently, ELA026—a novel monoclonal antibody targeting signal regulatory proteins (SIRP)-a/b1/g—has shown promising preliminary efficacy in clinical trials for treating mHLH. At the 29th European Hematology Association Annual Meeting (EHA 2024) held from June 13-16, Dr. Swaminathan Iyer from the University of Texas MD Anderson Cancer Center, USA and his team reported that ELA026 not only improved the response rate in treatment-naïve mHLH patients but also significantly enhanced their 2-month survival rate. This finding offers new hope for mHLH treatment. Oncology Frontier-Hematology Frontier invited Dr. Swaminathan Iyer to discuss the mechanism and clinical significance of ELA026 in mHLH treatment.

Dr. Shuhua Yi: China’s Perspective on Transforming Diagnostic and Treatment Standards for Waldenström Macroglobulinemia

By Mourabit Halima 2024.08.06

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide a platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , to discuss topics related to Waldenström macroglobulinemia (WM) in an in-depth academic exchange.

SYK Inhibitors, EHA Inauguration丨Dr. Bing Han: Innovative Dual Action of Syk Inhibitor Sovleplenib Promises New Frontiers in wAIHA Treatment

By Mourabit Halima 2024.08.06

The European Hematology Association (EHA) annual meeting, an international conference in the field of hematology, gathers numerous experts and scholars from around the world to share and deeply discuss innovative ideas and scientific and clinical research advancements in hematology, promoting continuous development in the field. At this year's conference, the research results on spleen tyrosine kinase (SYK) inhibitors received significant attention. Sovleplenib (HMPL-523), the first SYK inhibitor from China (as of publication date) to apply for market approval, showcased its potential in treating hematological diseases at this EHA meeting. Oncology Frontier - Hematology Frontier has invited Dr. Bing Han from Peking Union Medical College Hospital to provide an in-depth interpretation of the research on Sovleplenib in the field of warm autoimmune hemolytic anemia (wAIHA), aiming to provide references for clinical practice.

Dr. He Huang: Focusing on the Rise and Challenges of Cellular Immunotherapy | The 8th CSCO Hematology Academic Conference

By Mourabit Halima 2024.08.05

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.

Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

By Mourabit Halima 2024.08.05

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).